“Epigenetic-Modifying Enzymes in RUNX1-FPD”

Dr. Nimer will evaluate the ability of inhibitors or activators of epigenetic gene regulation to promote the differentiation, or inhibit the self-renewal, proliferation, and survival of RUNX1 mutant hematopoietic cells derived from cultures of human-induced pluripotent stem cells (iPSCs).

He will also generate a mouse model with combined mutations in RUNX1 and in a gene called ASXL1, which have been found to co-occur in a subset of RUNX1-FPD patients with AML, and test the activity of inhibitors or activators of epigenetic gene regulation in this model.